Quidel Showcases Comprehensive Suite of COVID-19 Testing Solutions at MEDLAB Middle East 2021

Sofia Q uses advanced fluorescence detection with an ultraviolet LED energy source and collects hundreds of data points on the test strip contained inside the Test Cassette. Quidel recently received an amended Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition to the Sofia and Sofia 2 line of Fluorescent Immunoassay Analyzers (FIA).

In addition to the Sofia Q, Quidel also exhibited other rapid diagnostic instrumented systems, including Sofia 2, and Sofia. Also on display were Quidel’s Sofia assays for rapid antigen COVID-19 diagnosis, including Sofia 2 SARS Antigen FIA and Sofia 2 Flu + SARS Antigen FIA, currently under EUA by the FDA. At MEDLAB Middle East 2021, Quidel also highlighted its other FDA-cleared and CLIA-waived tests, including Influenza A and B, Respiratory Syncytial Virus (RSV), Group A Strep, and a 15-minute finger-stick whole blood test for Lyme Disease.

Related Links:
Quidel Corporation